French drug company Sanofi-Aventis (SNY) has finally made a deal to buy biotech company Genzyme (GENZ) for $20.1 billion, about $74 a share. Genzyme shareholders will get a contingent value right that represents potential future payments if Lemtrada, the company’s multiple sclerosis drug, is a success. Sanofi has tried to close a deal for about nine months as the Genzyme board lobbied for a higher…
Continue reading Sanofi to Buy Genzyme in $20.1 Billion Deal
Sanofi to Buy Genzyme in $20.1 Billion Deal originally appeared on DailyFinance on Wed, 16 Feb 2011 06:30:00.
Filed Under: Company News, Earnings, Genzyme Corporation , Sanofi Aventis